Interleukin-6 (IL-6) is a multifunctional cytokine that plays a crucial role in immune response, inflammation, and hematopoiesis. The Interleukin-6 Soluble Receptor (IL-6SR) is a part of the IL-6 receptor complex, which is essential for the cytokine’s signal transduction. The soluble form of this receptor, often referred to as sIL-6R, can bind to IL-6 and modulate its activity. The human recombinant form of this receptor is produced using recombinant DNA technology, which allows for the production of large quantities of the protein for research and therapeutic purposes.
The IL-6 receptor complex consists of two main components: the IL-6 receptor (IL-6R) and the signal-transducing component gp130. The IL-6R can exist in both membrane-bound and soluble forms. The soluble form of IL-6R (sIL-6R) is generated either by proteolytic cleavage of the membrane-bound receptor or by alternative splicing of the IL-6R mRNA .
The sIL-6R retains the ability to bind IL-6 and can form a complex with the cytokine. This complex can then interact with gp130 on the surface of cells that do not express the membrane-bound IL-6R, thereby expanding the range of cells that can respond to IL-6. This process is known as trans-signaling and is crucial for the regulation of various physiological and pathological processes, including immune responses, inflammation, and cancer .
The human recombinant IL-6SR is typically produced in Escherichia coli (E. coli) or other suitable expression systems. The recombinant protein is often tagged with a histidine (His) tag to facilitate purification. The purification process usually involves affinity chromatography, where the His-tagged protein binds to a nickel or cobalt resin, allowing for the separation of the recombinant protein from other cellular components .
The human recombinant IL-6SR is widely used in immunological research to study the mechanisms of IL-6 signaling and its role in various diseases. It is also used in the development of therapeutic strategies for conditions such as autoimmune diseases, inflammatory disorders, and certain types of cancer. By modulating IL-6 signaling, researchers aim to develop treatments that can either enhance or inhibit the cytokine’s activity, depending on the therapeutic needs .